UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenalidomide, Luspatercept, Roxadustat and TP53 Mutations
Comments 0
Login to view comments.
Click here to Login
